These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23299001)

  • 61. Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial.
    Miao Y; Mzolo T; Pellegrini M
    Infect Dis Ther; 2019 Sep; 8(3):335-341. PubMed ID: 31377946
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):72-6. PubMed ID: 21270745
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevention of meningococcal infections in the first 2 years of life.
    Woods CR
    Pediatr Ann; 2013 Aug; 42(8):164-71. PubMed ID: 23910030
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
    Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
    Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
    Hedari CP; Khinkarly RW; Dbaibo GS
    Infect Drug Resist; 2014; 7():85-99. PubMed ID: 24729718
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.
    Assaf-Casals A; Dbaibo G
    Hum Vaccin Immunother; 2016 Jul; 12(7):1825-37. PubMed ID: 26900984
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages.
    Bröker M; Dull PM; Rappuoli R; Costantino P
    Vaccine; 2009 Sep; 27(41):5574-80. PubMed ID: 19619500
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: systematic review and meta-analysis.
    Pellegrino P; Perrone V; Radice S; Capuano A; Clementi E
    Pharmacol Res; 2015 Feb; 92():31-9. PubMed ID: 25447792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meningococcal conjugate vaccines policy update: booster dose recommendations.
    Committee on Infectious Diseases
    Pediatrics; 2011 Dec; 128(6):1213-8. PubMed ID: 22123893
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
    Klein NP; Shepard J; Bedell L; Odrljin T; Dull P
    Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2011 Jan; 29(5):1017-22. PubMed ID: 21134450
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.
    Bröker M; Cooper B; Detora LM; Stoddard JJ
    Infect Drug Resist; 2011; 4():137-47. PubMed ID: 21904459
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
    J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Sep; 58(37):1042-3. PubMed ID: 19779400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.